Clinical Trials · NCT02949284
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Rutgers, The State University of New Jersey
- Enrollment
- 90
- Start date
- Jun 2017
- Locations
- 2 sites, United States
- Primary endpoint
- Post-surgical potency rate defined as successful intercourse in half the attempts